Pharmacokinetics (ADME principles) US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Pharmacokinetics (ADME principles). These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Pharmacokinetics (ADME principles) US Medical PG Question 1: What is the primary mechanism for iron absorption in the duodenum?
- A. Simple diffusion
- B. Passive paracellular transport
- C. Endocytosis
- D. DMT1 transporter (Correct Answer)
Pharmacokinetics (ADME principles) Explanation: ***DMT1 transporter***
- The **divalent metal transporter 1 (DMT1)** is the primary mechanism for absorbing **non-heme iron (ferrous iron, Fe2+)** into duodenal enterocytes.
- This active transport process is pH-dependent and drives iron uptake against a concentration gradient.
*Simple diffusion*
- Applies to the movement of substances down their concentration gradient without the aid of membrane proteins, which is not the main mechanism for iron due to its ionic nature.
- While some highly lipid-soluble substances can cross membranes this way, metal ions like iron require specific transporters.
*Passive paracellular transport*
- Involves substances moving *between* cells, rather than *through* them, often occurring in leaky epithelia.
- While some fluid and electrolytes may use this route, it is not the primary or regulated pathway for iron absorption.
*Endocytosis*
- A process where cells engulf substances by forming vesicles from the plasma membrane.
- While some macromolecules are absorbed via endocytosis, it is not the major mechanism for absorbing dietary iron in the duodenum.
Pharmacokinetics (ADME principles) US Medical PG Question 2: A 65-year-old female patient with a past medical history of diabetes mellitus and an allergy to penicillin develops an infected abscess positive for MRSA on the third day of her hospital stay. She is started on an IV infusion of vancomycin at a dose of 1000 mg every 12 hours. Vancomycin is eliminated by first-order kinetics and has a half life of 6 hours. The volume of distribution of vancomycin is 0.5 L/kg. Assuming no loading dose is given, how long will it take for the drug to reach 94% of its plasma steady state concentration?
- A. 30 hours
- B. 12 hours
- C. 6 hours
- D. 18 hours
- E. 24 hours (Correct Answer)
Pharmacokinetics (ADME principles) Explanation: ***24 hours***
- For a drug eliminated by **first-order kinetics**, it takes approximately **4 half-lives** to reach **93.75%** of steady state concentration, which is conventionally rounded to **94%**.
- Since the half-life of vancomycin is **6 hours**, reaching 94% of steady state requires: 4 × 6 hours = **24 hours**.
- This follows the pharmacokinetic principle that each half-life brings the drug closer to steady state: 1 t½ = 50%, 2 t½ = 75%, 3 t½ = 87.5%, 4 t½ = 93.75%.
*30 hours*
- This duration represents **five half-lives** (5 × 6 hours), at which point approximately **96.875%** (often rounded to 97%) of steady state would be reached.
- This exceeds the 94% target specified in the question.
*18 hours*
- This duration represents **three half-lives** (3 × 6 hours), at which point approximately **87.5%** of steady state concentration would be reached.
- This falls short of the 94% target.
*12 hours*
- This duration represents **two half-lives** (2 × 6 hours), at which point approximately **75%** of steady state concentration would be reached.
- This is insufficient time to reach 94% of plasma steady state concentration.
*6 hours*
- This duration represents **one half-life**, at which point approximately **50%** of steady state concentration would be reached.
- This is far too short to achieve near-steady state levels.
Pharmacokinetics (ADME principles) US Medical PG Question 3: A scientist is studying the excretion of a novel toxin X by the kidney in order to understand the dynamics of this new substance. He discovers that this new toxin X has a clearance that is half that of inulin in a particular patient. This patient's filtration fraction is 20% and his para-aminohippuric acid (PAH) dynamics are as follows:
Urine volume: 100 mL/min
Urine PAH concentration: 30 mg/mL
Plasma PAH concentration: 5 mg/mL
Given these findings, what is the clearance of the novel toxin X?
- A. 1,500 mL/min
- B. 600 mL/min
- C. 300 mL/min
- D. 60 mL/min (Correct Answer)
- E. 120 mL/min
Pharmacokinetics (ADME principles) Explanation: ***60 ml/min***
- First, calculate the **renal plasma flow (RPF)** using PAH clearance: RPF = (Urine PAH conc. × Urine vol.) / Plasma PAH conc. = (30 mg/mL × 100 mL/min) / 5 mg/mL = 600 mL/min.
- Next, calculate the **glomerular filtration rate (GFR)**, which is the clearance of inulin. GFR = RPF × Filtration Fraction = 600 mL/min × 0.20 = 120 mL/min. Toxin X clearance is half of inulin clearance, so 120 mL/min / 2 = **60 mL/min**.
*1,500 ml/min*
- This value is likely obtained if an incorrect formula or conversion was made, possibly by misinterpreting the units or the relationship between GFR, RPF, and filtration fraction.
- It significantly overestimates the clearance for a substance that is cleared at half the rate of inulin.
*600 ml/min*
- This value represents the **renal plasma flow (RPF)**, calculated using the PAH clearance data.
- It does not account for the filtration fraction or the fact that toxin X clearance is half of inulin clearance (GFR).
*300 ml/min*
- This value would be obtained if the renal plasma flow (RPF) was incorrectly halved, or if an intermediate calculation was misinterpreted as the final answer.
- It does not align with the given filtration fraction and the relationship between toxin X and inulin clearance.
*120 ml/min*
- This value represents the **glomerular filtration rate (GFR)**, which is equal to the clearance of inulin (RPF × Filtration Fraction = 600 mL/min × 0.20 = 120 mL/min).
- The question states that the clearance of toxin X is **half** that of inulin, so this is an intermediate step, not the final answer.
Pharmacokinetics (ADME principles) US Medical PG Question 4: A research group wants to assess the safety and toxicity profile of a new drug. A clinical trial is conducted with 20 volunteers to estimate the maximum tolerated dose and monitor the apparent toxicity of the drug. The study design is best described as which of the following phases of a clinical trial?
- A. Phase 0
- B. Phase III
- C. Phase V
- D. Phase II
- E. Phase I (Correct Answer)
Pharmacokinetics (ADME principles) Explanation: ***Phase I***
- **Phase I clinical trials** involve a small group of healthy volunteers (typically 20-100) to primarily assess **drug safety**, determine a safe dosage range, and identify side effects.
- The main goal is to establish the **maximum tolerated dose (MTD)** and evaluate the drug's pharmacokinetic and pharmacodynamic profiles.
*Phase 0*
- **Phase 0 trials** are exploratory studies conducted in a very small number of subjects (10-15) to gather preliminary data on a drug's **pharmacodynamics and pharmacokinetics** in humans.
- They involve microdoses, not intended to have therapeutic effects, and thus cannot determine toxicity or MTD.
*Phase III*
- **Phase III trials** are large-scale studies involving hundreds to thousands of patients to confirm the drug's **efficacy**, monitor side effects, compare it to standard treatments, and collect information that will allow the drug to be used safely.
- These trials are conducted after safety and initial efficacy have been established in earlier phases.
*Phase V*
- "Phase V" is not a standard, recognized phase in the traditional clinical trial classification (Phase 0, I, II, III, IV).
- This term might be used in some non-standard research contexts or for post-marketing studies that go beyond Phase IV surveillance, but it is not a formal phase for initial drug development.
*Phase II*
- **Phase II trials** involve several hundred patients with the condition the drug is intended to treat, focusing on **drug efficacy** and further evaluating safety.
- While safety is still monitored, the primary objective shifts to determining if the drug works for its intended purpose and at what dose.
Pharmacokinetics (ADME principles) US Medical PG Question 5: A 26-year-old man comes to the emergency department because of a 1-week history of worsening fatigue, nausea, and vomiting. Six weeks ago, he was diagnosed with latent tuberculosis and appropriate low-dose pharmacotherapy was initiated. Physical examination shows right upper quadrant tenderness and scleral icterus. Laboratory studies show elevated aminotransferases. Impaired function of which of the following pharmacokinetic processes is the most likely explanation for this patient's symptoms?
- A. Acetylation (Correct Answer)
- B. Glucuronidation
- C. Hydrolysis
- D. Sulfation
- E. Reduction
Pharmacokinetics (ADME principles) Explanation: ***Acetylation***
- This patient is exhibiting symptoms of **hepatotoxicity** (fatigue, nausea, vomiting, RUQ tenderness, scleral icterus, elevated aminotransferases) after starting low-dose pharmacotherapy for latent tuberculosis. The most common drug used for latent TB is **isoniazid**, which is primarily metabolized by **N-acetylation**.
- Impaired acetylation, particularly in **slow acetylators**, can lead to higher plasma concentrations of isoniazid and its toxic metabolites, increasing the risk of **drug-induced liver injury**.
*Glucuronidation*
- **Glucuronidation** is a Phase II metabolic pathway that conjugates drugs with **glucuronic acid** to increase water solubility and facilitate excretion.
- While important for the metabolism of many drugs and endogenous substances (e.g., bilirubin), it is not the primary mechanism of metabolism or the main pathway implicated in the hepatotoxicity of **isoniazid**.
*Hydrolysis*
- **Hydrolysis** is a chemical reaction in which water is used to break down a compound, often involving ester or amide bonds.
- This process is not the primary metabolic pathway for **isoniazid**, nor is impaired hydrolysis a common cause of its hepatotoxicity.
*Sulfation*
- **Sulfation** is a Phase II metabolic reaction that conjugates drugs with a **sulfate group**, typically for detoxification and excretion.
- While various drugs undergo sulfation, it is not the dominant metabolic pathway for **isoniazid**, and impaired sulfation is not typically associated with isoniazid-induced hepatotoxicity.
*Reduction*
- **Reduction** reactions involve the gain of electrons or hydrogen atoms, or the loss of oxygen, and are part of drug metabolism for certain compounds.
- However, reduction is not the primary clearance mechanism for **isoniazid**, and abnormal reduction is not commonly implicated in its hepatotoxic effects.
More Pharmacokinetics (ADME principles) US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
